论文部分内容阅读
目的观察急性ST段抬高心肌梗死(STEMI)患者血浆B型钠尿肽(BNP)的变化情况及心血管不良事件发生的关系,为BNP在临床中的检测价值提供理论依据。方法选取2007-01-2008-12深圳市孙逸仙心血管医院收治的STEMI患者84例为对象,发病后24～96h获取血浆检测其BNP浓度,并记录随访2a内的心血管不良事件的发生情况。结果 STEMI患者与健康对照组相比,血浆BNP浓度明显高于后者。84例中有39例有各种心血管不良事件发生,其BNP水平与正常对照组相比差异有统计学意义。结论血浆BNP水平是急性心肌梗死不良预后的危险因素,对于STEMI患者而言,BNP的动态监测对指导治疗以及远期预后方面具有重要意义。
Objective To observe the changes of plasma B-type natriuretic peptide (BNP) and the incidence of cardiovascular adverse events in patients with acute ST-segment elevation myocardial infarction (STEMI), and to provide a theoretical basis for the detection of BNP in clinical practice. Methods Eighty-four STEMI patients admitted to Sun Yat-sen Cardiovascular Hospital of Shenzhen City from January 2007 to December 2008 were selected for plasma BNP concentration from 24 to 96 h after onset. The incidence of cardiovascular adverse events during follow-up was recorded. Results Compared with the healthy control group, plasma BNP levels in STEMI patients were significantly higher than those in the control group. Among the 84 cases, 39 cases had various cardiovascular adverse events, and their BNP levels were significantly different from those of the normal control group. Conclusions Plasma BNP level is a risk factor for poor prognosis in acute myocardial infarction. For STEMI patients, dynamic monitoring of BNP is of great importance in guiding treatment and long-term prognosis.